noom and glp-1 Med Noom

In February, FDA announced a crackdown on misleading marketing

For the scenario of "Currently Available Treatment," research data suggests Tirzepatide may be more relevant

However, some studies suggest that these side effects may be slightly more common or intense with tirzepatide, likely due to its dual-agonist action and higher efficacy

What should I do when traveling Plan ahead

GLP-1 lowers postprandial glucose excursion by potentiating glucose-stimulated insulin secretion from pancreatic -cells and has also recently been shown to promote -cell survival in rodents 2

Together, these developments represent the sharpest acceleration in the treatment of obesity that American public health has witnessed in decades